Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox FCT vs Phlebotomy in Hereditary Hemochromatosis
NCT03203850Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of deferasirox in hereditary hemochromatosis (HH) (2 arms), sponsored by Novartis. Primary endpoint: Proportion of Patients Achieving Target SF <= 100 μg/L. Started Jan 2018; status: terminated.
02
Drugs
deferasirox
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NCT03203850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203850.